Genzyme Files Applications for Approval of Mozobil in the United States ...(hese statements are subject to risks and...)

Date:6/17/2008

hese statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward- looking statements. These risks and uncertainties include, among others, the failure to receive regulatory approval to commercialize Mozobil in the U.S., Europe or other countries, the lack of adoption of the product in other therapeutic areas, the inability to change current treatment protocols and risks associated with commercial launch and the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending March 31, 2008. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800- 905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact:

Bo Piela

(617) 768-6579

Investor Contact:

Patrick Flanigan

(617) 768-6563

'/>"/>

SOURCE Genzyme Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Genzyme Boosts Quality Using Dyadem Quality Lifecycle Management
2. Awareness of Genzymes Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
3. Genzyme Reports Strong First-Quarter Growth
4. Genzyme to Build New R&D Center in Beijing
5. Genzyme Provides Update on Myozyme(R) Manufacturing
6. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
7. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
8. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
9. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
10. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
11. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)